BIO Form 4: CEO vesting of RSUs and $295.43/share purchase reported
Rhea-AI Filing Summary
Norman D. Schwartz, Chairman & CEO of Bio-Rad Laboratories (BIO), reported insider transactions related to Class A and Class B common stock. The filing shows vested restricted stock units converted into 3,455 Class A shares and a separate purchase of 1,528 Class A shares at $295.43 each, leaving him with 443,434 Class A shares direct ownership. The report also discloses 361,466 Class B shares held directly, 13,006 Class B shares held indirectly by spouse, and 4,060,054 Class B shares held indirectly by Blue Raven Partners, L.P. Restricted stock units vest over four years at 25% per year.
Positive
- Realized equity alignment: Vesting of 16,439 RSUs (with 3,455 vested reported) converts compensation into equity, aligning management with shareholders
- Open-market purchase: Acquisition of 1,528 Class A shares at $295.43 indicates additional personal investment by the CEO
- Clear disclosure: Distinct reporting of direct and indirect holdings, including spouse and partnership, improves governance transparency
Negative
- Concentrated indirect holdings: 4,060,054 Class B shares held by Blue Raven Partners, L.P. indicate significant control concentration
- Limited immediate liquidity signal: Transactions are primarily vesting and a small purchase; no significant sale or diversification disclosed
Insights
TL;DR: Insider converted RSUs and purchased shares, modestly increasing direct Class A holdings; substantial indirect Class B holdings remain concentrated.
The transactions combine routine compensation vesting with a market purchase at $295.43 per share, increasing direct Class A holdings to 443,434 shares. The large indirect position through Blue Raven Partners, L.P. (4,060,054 Class B shares) maintains concentrated control influence without changing reported beneficial ownership materially. For investors, these filings show alignment through equity compensation realization and a small open-market purchase, but no change in control or divestiture.
TL;DR: Vesting RSUs and a share purchase are routine; disclosure highlights both direct and disclaimed indirect holdings, relevant for governance transparency.
The report clearly separates direct ownership from disclaimed indirect interests, noting spouse-held shares and partnership holdings. The vesting schedule (25% annually) clarifies timing of future share deliveries. No departures, option exercises at non-market prices, or related-party transfers are reported. This filing is a routine governance disclosure that maintains transparency about potential voting influence and economic interest.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 3,455 | $0.00 | -- |
| Exercise | Bio-Rad A Common Stock | 3,455 | $0.00 | -- |
| Tax Withholding | Bio-Rad A Common Stock | 1,528 | $295.43 | $451K |
| Grant/Award | Restricted Stock Units | 16,439 | $0.00 | -- |
| holding | Bio-Rad B Common Stock | -- | -- | -- |
| holding | Bio-Rad B Common Stock | -- | -- | -- |
| holding | Bio-Rad B Common Stock | -- | -- | -- |
Footnotes (1)
- Shares of Class A common stock acquired on the vesting of restricted stock units. The reporting person disclaims beneficial ownership of these shares. The shares are held by a limited partnership of which the reporting person is a limited and general partner. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.
